Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy

Hormone and Metabolic Research

Volumn 33, Issue 5, 2001, Pages 300-306

  Boehm, B O ^a   Lang, G K ^a   Jehle, P M ^a   Feldmann, B ^a   Lang, G E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Diabetic retinopathy; Growth hormone; Insulin like growth factor I; Octreotide treatment

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LASER COAGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HORMONES; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OCTREOTIDE; OPHTHALMOLOGIC SURGICAL PROCEDURES; PATIENT COMPLIANCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 0034961440     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15282     Document Type: Article

References (33)

1. The epidemiology of eye disease
2. DRS Report No. 8. Photocoagulation treatment of proliferative diabetic retinopathy
3. ETDRS Report No. 8 & 9. Early photocoagulation for diabetic retinopathy
4. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
7. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
8. Shedding light on blindness
9. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
10. Pituitary ablation in the treatment of diabetic retinopathy
11. Pituitary ablation for diabetic retinopathy
12. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy
13. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation
14. Survival following α particle pituitary irradiation for diabetic retinopathy
15. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes
16. Diabetic microvascular complications and growth factors
17. Growth factors in the pathogenesis of diabetic retinopathy
18. Growth hormone suppression and nonproliferative diabetic retinopathy: A preliminary feasibility study
19. Long-term visual outcome of diabetic patients treated with pan-retinal photocoagulation
20. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion
21. Diabetic retinopathy
22. Treatment of proliferative diabetic retinopathy
23. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy
24. Diabetic retinopathy is associated with decreased serum levels of flee IGF-I and changes of IGF-binding proteins
25. Drug therapy - Octreotide
26. Effect of a long-acting somatostatin analogue (B1M23014) on proliferative diabetic retinopathy: A pilot study
27. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995
28. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy
29. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus
30. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study
31. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: A potential treatment for ocular neovascularization
32. Essential role of growth hormone in ischemia-induced retinal neovascularizations
33. Early worsening of diabetic retinopathy in the diabetes control and complications trial